Re-Evaluation of Clinical Dementia Diagnoses with Pittsburgh Compound B Positron Emission Tomography

Alzheimer’s disease · Dementia with Lewy bodies · Frontotemporal dementia · β-Amyloid · Amyloid biomarker · Pittsburgh compound B positron emission tomography · [ 18 F]Fluoro-2-deoxy- D-glucose positron emission tomography · Neuropsychological tests · Trail Making Test, part A · Episodic memory Objectives: There is an overlap regarding Pittsburgh compound B (PIB) retention in patients clinically diagnosed as Alzheimer’s disease (AD) and non-AD dementia. The aim of the pres-ent study was to investigate whether there are any differences between PIB-positive and PIB-negative patients in a mixed cohort of patients with neurodegenerative dementia of mild se-verity regarding neuropsychological test performance and regional cerebral glucose metabolism measured with [ 18 F]fluoro-2-deoxy- D-glucose (FDG) positron emission tomogra-phy (PET). Methods: Eighteen patients clinically diagnosed as probable AD or frontotemporal dementia were examined with PIB PET, FDG PET and neuropsychological tests and followed for 5–9 years in a clinical setting. Results: The PIB-positive patients (7 out of 18) had slower psychomotor speed and more impaired visual episodic memory than the PIB-negative pa